Literature DB >> 10823420

CD40 expression on human lung cancer correlates with metastatic spread.

M S Sabel1, M Yamada, Y Kawaguchi, F A Chen, H Takita, R B Bankert.   

Abstract

PURPOSE: The poor prognosis associated with lung cancer is related to the high incidence of regional and distant metastasis. There is a crucial need to identify parameters that can predict a tendancy to metastatic spread to allow better prognostic evaluation and therapeutic approach.
METHODS: Using flow cytometry we evaluated 18 human lung cancer cell lines for the expression of different surface markers on lung cancers suggested to be possible prognostic parameters, including epidermal growth factor receptor (EGFR), intercellular adhesion molecule 1 (ICAM-1), Fas and CD40.
RESULTS: No correlation was found between tumor prognosis and EGFR, ICAM-1 or Fas. However, a statistically significant correlation was found between the surface expression of CD40 and the metastatic spread of the tumor. In this study, 14 of 18 lung cancer cell lines (78%) expressed CD40 on their surface. All of the 4 tumors that were CD40-negative, were stage I tumors, without any evidence of regional or distant metastasis. Of the 14 tumors that expressed CD40, all but 1 (93%) had either nodal or systemic metastasis at the time of diagnosis. Patients whose tumors were CD40-negative showed a significantly better N stage, overall stage at presentation and survival than those patients with CD40-positive patients. No significant differences between the two groups were observed in tumor size, gender, age, histology, differentiation or preoperative therapy.
CONCLUSIONS: These results suggest that CD40 expression on lung cancer may play a role in metastatic spread, and also may serve as a prognostic marker and an indicator of advanced disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10823420     DOI: 10.1007/s002620050608

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  5 in total

Review 1.  Immunotherapies for bladder cancer: a new hope.

Authors:  Farhad Fakhrejahani; Yusuke Tomita; Agnes Maj-Hes; Jane B Trepel; Maria De Santis; Andrea B Apolo
Journal:  Curr Opin Urol       Date:  2015-11       Impact factor: 2.309

Review 2.  Immunotherapy in the treatment of non-small cell lung cancer.

Authors:  Raghav Sundar; Richie Soong; Byoung-Chul Cho; Julie R Brahmer; Ross A Soo
Journal:  Lung Cancer       Date:  2014-05-14       Impact factor: 5.705

Review 3.  Varied functions of immune checkpoints during cancer metastasis.

Authors:  Ali Safarzadeh; Mohsen Alizadeh; Fatemeh Beyranvand; Reza Falavand Jozaaee; Khalil Hajiasgharzadeh; Amir Baghbanzadeh; Afshin Derakhshani; Antonella Argentiero; Behzad Baradaran; Nicola Silvestris
Journal:  Cancer Immunol Immunother       Date:  2020-09-09       Impact factor: 6.968

4.  Genetic Variations of CD40 and LTβR Genes Are Associated With Increased Susceptibility and Clinical Outcome of Non-Small-Cell Carcinoma Patients.

Authors:  Foteinos-Ioannis D Dimitrakopoulos; Anna G Antonacopoulou; Anastasia E Kottorou; Melpomeni Kalofonou; Nikolaos Panagopoulos; Dimitrios Dougenis; Thomas Makatsoris; Vasiliki Tzelepi; Angelos Koutras; Haralabos P Kalofonos
Journal:  Front Oncol       Date:  2021-09-17       Impact factor: 6.244

5.  Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.

Authors:  Hye Won Chung; Jong-Baeck Lim
Journal:  J Transl Med       Date:  2014-04-21       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.